Skip to main content

AccessPak for HIV PEP Expanded with Viracept and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil).

Minor

Tenofovir Food

Minor Food Interaction

Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.

References (1)
  1. (2001) "Product Information. Viread (tenofovir)." Gilead Sciences

Switch to consumer interaction data

AccessPak for HIV PEP Expanded with Viracept drug interactions

There are 699 drug interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil).

AccessPak for HIV PEP Expanded with Viracept disease interactions

There are 11 disease interactions with AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil) which include:

Report options

Loading...
QR code containing a link to this page

More about AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer